Table 5. Distribution proportion and incidence rate (100 person per year) of endpoint events in different risk stratifications.
| Study | CHADS2(revised)† |
CHA2DS2-VASc |
||||||||||
| Low risk |
Moderate risk |
High risk |
Low risk |
Moderate risk |
High risk |
|||||||
| Rate | Distribute ratio (%) | Rate | Distribute ratio (%) | Rate | Distribute ratio (%) | Rate | Distribute ratio (%) | Rate | Distribute ratio (%) | Rate | Distribute ratio (%) | |
| Poli, et al.[9] | 0.0 | 5.0 | 3.9 | 20.0 | 6.2 | 75.0 | 0.0 | 2.0 | 2.8 | 5.0 | 5.0 | 93.0 |
| Lip, et al.[4] | 1.4 | 20.0 | 1.9 | 35.0 | 3.1 | 45.0 | 0.0 | 10.0 | 0.6 | 15.0 | 3.0 | 76.0 |
| Lip, et al.[10] | 0.0 | 2.0 | 0.9 | 31.0 | 2.1 | 2.0 | NA | 0.0 | 0.5 | 6.0 | 1.7 | 94.0 |
| Lin, et al.[12] | 0.5 | 30.0 | 1.0 | 37.0 | NA | 34.0 | 0.4 | 8.0 | 0.5 | 19.0 | NA | 73.0 |
| Sandhu, et al.[13],§ | 1.1 | NA | 3.2 | NA | 8.4 | NA | NA | 0.0 | 1.3 | NA | 6.5 | NA |
| Sandhu, et al.[13],△ | 1.4 | NA | 2.1 | NA | 6.7 | NA | NA | 0.0 | 4.1 | NA | 9.9 | NA |
| Friberg, et al.[15] | 0.9 | 15.0 | 5.2 | 25.0 | 12.3 | 6.0 | 0.3 | 6.0 | 1.9 | 7.0 | 8.9 | 87.0 |
| Van Staa, et al.[14] | 1.0 | NA | 3.7 | NA | 8.3 | NA | 0.5 | 8.6 | 1.1 | 12.7 | 4.6 | 78.7 |
| Olesen, et al.[11],* | 1.7 | 21.6 | 4.8 | 31.4 | 12.3 | 47.0 | 0.8 | 8.4 | 2.0 | 12.0 | 8.8 | 79.6 |
| Average# | 0.9 | 15.6 | 3.0 | 29.9 | 7.4 | 34.8 | 0.3 | 4.8 | 1.6 | 11.0 | 6.1 | 83.0 |
*1-year follow-up within the study of Olesen. #The average rate is combined with TE and stoke. Separately the average incidence rates of TE in the low, medium, high risk were 0.98%, 3.04%, 8.93% for CHADS2 and 0.78%, 2.88%, 5.93% for CHA2DS2-VASc, and average rates of stroke were 0.78%, 2.88%, 5.93% for CHADS2 and 0.27%, 1.48%, 4.63% for CHA2DS2-VASc. †CHADS2–revised: low risk score 0, moderate risk score 1, high risk score 2–6. §&△: anticoagulant and non-anticoagulant subgroups within the study of Sandhu, respectively. TE: systemic thromboembolism or stroke; NA: not available.